Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
S Loi, S Michiels, R Salgado, N Sirtaine, V Jose, D Fumagalli, P-L Kellokumpu-Lehtinen, P Bono, V Kataja, C Desmedt, MJ Piccart, S Loibl, C Denkert, MJ Smyth, H Joensuu, C Sotiriou
Annals of Oncology | OXFORD UNIV PRESS | Published : 2014
Awarded by European Union
Awarded by Cancer Foundation Finland sr
This study was funded by the European Union Framework 7 program (EU-FP7) RESPONSIFY project (No. 278659) and the Breast Cancer Research Foundation (BCRF), NY. The funding source had no role in the study design, data analysis, data collection, data interpretation or writing of the report. SL, SM, and CS are supported by the Breast Cancer Research Foundation, NY. SL is supported by the Fonds JC Heuson, Belgium, the National Health and Medical Council of Australia (NH&MRC), and Cancer Council Victoria. MJS is supported by a NH&MRC Australia Fellowship and the Susan G. Komen Breast Cancer Foundation. HJ is supported by the Academy of Finland, Cancer Society for Finland, the Sigrid Juselius Foundation, and the Research Funds of Helsinki University Central Hospital.